Evidence map›Paper›PMID 40528051›Full record

ArticleEMBO reports2025

GPNMB marks a quiescent cell population in melanoma and promotes metastasis formation.

Fiorenza Lotti, Marine Melixetian, Thalia Vlachou, Marco S Nobile, Leone Bacciu, Marco Malferrari, Nicolò Quaresima, Stefania Rapino, Federica Marocchi, Massimo Barberis and 9 more

Abstract read
In one paragraph

Article in EMBO reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. iScience · 2026
    Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Fiorenza LottiDepartment of Experimental Oncology, European Institute of Oncology IRCCS, Milan, Italy.ORCID 0000-0003-4897-0420
Marine MelixetianDepartment of Experimental Oncology, European Institute of Oncology IRCCS, Milan, Italy.ORCID 0000-0002-8454-8262
Thalia VlachouDepartment of Experimental Oncology, European Institute of Oncology IRCCS, Milan, Italy.ORCID 0000-0001-5264-3591
Marco S NobileDepartment of Environmental Science, Computer Science and Statistics, University of Ca' Foscari, Venice, Italy.ORCID 0000-0002-7692-7203
Leone BacciuDepartment of Environmental Science, Computer Science and Statistics, University of Ca' Foscari, Venice, Italy.
Marco MalferrariDepartment of Chemistry "Giacomo Ciamician", Università di Bologna, Via Selmi 2, 40126, Bologna, Italy.ORCID 0000-0003-1613-1593
Nicolò QuaresimaDepartment of Chemistry "Giacomo Ciamician", Università di Bologna, Via Selmi 2, 40126, Bologna, Italy.ORCID 0009-0002-0224-073X
Stefania RapinoDepartment of Chemistry "Giacomo Ciamician", Università di Bologna, Via Selmi 2, 40126, Bologna, Italy.
Federica MarocchiDepartment of Experimental Oncology, European Institute of Oncology IRCCS, Milan, Italy.ORCID 0000-0002-5610-5499
Massimo BarberisDepartment of Experimental Oncology, European Institute of Oncology IRCCS, Milan, Italy.ORCID 0000-0002-0943-4804
Chiara SorianiDepartment of Experimental Oncology, European Institute of Oncology IRCCS, Milan, Italy.ORCID 0000-0003-4363-6597
Barbara GalloDepartment of Experimental Oncology, European Institute of Oncology IRCCS, Milan, Italy.
Velia MolloDepartment of Experimental Oncology, European Institute of Oncology IRCCS, Milan, Italy.
Ilaria FerrarottoDepartment of Experimental Oncology, European Institute of Oncology IRCCS, Milan, Italy.
Daniela BossiDepartment of Experimental Oncology, European Institute of Oncology IRCCS, Milan, Italy.
Pier Francesco FerrucciDepartment of Experimental Oncology, European Institute of Oncology IRCCS, Milan, Italy.ORCID 0000-0001-6255-5851
Pier Giuseppe PelicciDepartment of Experimental Oncology, European Institute of Oncology IRCCS, Milan, Italy.ORCID 0000-0002-5076-2316
Lucilla LuziDepartment of Experimental Oncology, European Institute of Oncology IRCCS, Milan, Italy.ORCID 0000-0002-8746-4179
Luisa LanfranconeDepartment of Experimental Oncology, European Institute of Oncology IRCCS, Milan, Italy. luisa.lanfrancone@ieo.it.ORCID 0000-0002-4523-3815

Funding

Associazione Italiana Ricerca sul Cancro IG 2023 ID 28890Fondazione Umberto Veronesi (Umberto Veronesi Foundation) FellowshipMinistero della Salute (Italy Ministry of Health) GR-2018-12367747Ministero della Salute (Italy Ministry of Health) Ricerca Corrente and 5x1000 funds
6 · The paper itself

Abstract

Melanoma exhibits high intratumoral heterogeneity, characterized by a diverse population of cells undergoing dynamic transitions between cellular states. These adaptive changes enable melanoma cells to survive in the harsh tumor microenvironment, acquire drug resistance, and metastasize. One such state, quiescence, has been linked to both relapse and drug resistance, but its underlying biology and molecular mechanisms remain poorly understood. Our study challenges the conventional understanding of melanoma quiescence. Contrary to the notion of a rare, unique subpopulation, we demonstrate that quiescence is a highly dynamic state accessible to most, if not all, melanoma cells. This state is exquisitely sensitive to microenvironmental cues. We identify GPNMB as a marker of quiescence, that is expressed in both primary and metastatic tumors. GPNMB-positive cells exhibit a pro-metastatic phenotype and are enriched in metastatic sites, suggesting a potential role for quiescence in tumor dissemination. Our findings position GPNMB as a valuable marker for isolating quiescent melanoma cells and as a potential therapeutic target to tackle metastasis.

Indexed as

Biomarkers, TumorMelanomaMembrane GlycoproteinsSkin NeoplasmsAnimalsAntineoplastic AgentsBiopsyCell Line, TumorGene Expression Regulation, NeoplasticHumansMiceMolecular Targeted TherapySkinTumor MicroenvironmentUp-RegulationXenograft Model Antitumor AssaysAntineoplastic AgentsBiomarkers, TumorGPNMB protein, humanMembrane GlycoproteinsHypoxiaMelanomaMetastasisQuiescenceTarget Therapy

Identifiers

PMID40528051
PMCPMC12332017

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.